July 28, 2023 Comments Off on Review of 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020: A Focus on Intellectual Property and Regulatory Considerations Posted in: Insights A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as approved by the USFDA from 2010 to 2020. The study…
The post Review of 505(b)(2) Drug Products Approved by USFDA from 2…
July 28, 2023 Comments Off on New patent for Janssen Biotech drug BALVERSA Posted in: Patent Added Annual Drug Patent Expirations for BALVERSA Balversa is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are five patents…
The post New patent for Janssen Biotech drug BALVERSA appeared first on Dr…
